Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2025-01-28 DOI:10.1093/cid/ciae626

Marie Yan, Alejandro Hernandez, Kelvin K Chan, Matthew B Stanbrook, Phillip S Blanchette, James C Johnston, Samantha M Lee, Liane Macdonald, Melissa Richard-Greenblatt, Theodore K Marras, Sarah K Brode

引用次数: 0

Abstract

In this population-based study, we examined the risk of nontuberculous mycobacterial disease associated with immune checkpoint inhibitors among people with cancer. Using a nested case-control design, we identified 184 cases and 714 matched controls; there was no significant association on conditional logistic regression (adjusted odds ratio, 0.51 [95% confidence interval, .17-1.50]; P = .22).

查看原文本刊更多论文

在这项基于人群的研究中，我们考察了癌症患者罹患与免疫检查点抑制剂相关的非结核分枝杆菌疾病的风险。通过巢式病例对照设计，我们确定了 184 例病例和 714 例匹配对照；条件逻辑回归结果显示，两者之间没有显著关联（调整后的几率比为 0.51 [95% 置信区间为 0.17-1.50]；P = 0.22）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.